CathVision has developed PFAnalyzer, a method for calculating residual energy in the tissue after PFA delivery that can help form the basis of an objective, easy-to-use marker of success in procedure.

CathVision announces data from the PVISION trial demonstrating the ability of the ECGenius System’s predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures.

CathVision announces the the launch of ECGenius 3.1, an advanced version of the ECGeniusTM System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.

CathVision announces the FDA clearance and commercial availability of the PVI Analyzer and Signal Complexity algorithms. These algorithms are part of the CARDIALYTICS suite of artificial intelligence-powered analytics integrated into the ECGenius System.

CathVision announces its most recent financing round of $9 million from investors. The financing will help advance commercial operations driving adoption of the ECGenius™ System, the company’s innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures.

CathVision announces an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics. HRS 2023 is being held May 19-21 in New Orleans; attendees can visit CathVision during the conference at booth 1442.

CathVision announces significant milestones demonstrating both the clinical and commercial success of the ECGenius™ System.

CathVision announces the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF. Ten patients have been treated to date at NYU Langone Health, one of the nation’s premier academic medical centers.

CathVision Announces Close Of $7.2 Million Financing Round Funding Will Accelerate Commercialization of the ECGenius™ System and Expand Development of Analytic Modules Copenhagen, DENMARK, AUGUST 17, 2022 /PRNewswire/ – CathVision,

CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology ECGenius™ Sets a New Standard for ECG Signal Acquisition, Interpretation and Therapy Support COPENHAGEN, Denmark, May 4,

CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology University of Vermont Medical Center Initiates Evaluation of the ECGenius™

CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study Researchers to Examine Efficacy of Using AI Algorithm to Confirm Pulmonary Vein Isolation COPENHAGEN, Denmark and MINNETONKA, Minn., Oct. 26,